OncoZenge AB (8LY) Price & Analysis

0 Followers

8LY Stock Chart & Stats

€0.59

-€0.02(-7.82%)

At close: Jan 08 4:00 PM EST

€0.59

-€0.02(-7.82%)

Day’s Range― - ―

52-Week Range€0.27 - €0.63

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€7.08M

Enterprise Value€108.32

Total Cash (Recent Filing)€749.00K

Total Debt (Recent Filing)€7.50M

Price to Earnings (P/E)―

Beta0.65

Next Earnings

Nov 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.92

Shares Outstanding25,048,912

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)-139.70

Price to Sales (P/S)30.78

P/FCF Ratio-6.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.07

Revenue Forecast (FY)€448.04K

Bulls Say, Bears Say

Bulls Say

Revenue GrowthRevenue more than doubled year over year, indicating improving commercialization traction for the company’s product. Although the base remains small, sustained top-line expansion could strengthen operating leverage and provide a foundation for scaling over the coming quarters.

Positive Gross ProfitPositive gross profit shows that current revenue generates value before operating expenses, an important foundation for a pharmaceutical commercialization model. If revenue continues to expand, this contribution could help absorb the existing cost base and improve earnings quality over time.

Improving Free Cash FlowFree cash flow improved versus 2025, suggesting some progress in the relationship between spending and cash generation. It remains negative and does not remove funding risk, but continued improvement could gradually reduce the capital required to support operations.

Bears Say

Persistent Operating LossesLarge recurring losses show that the current cost base remains far above the company’s revenue scale. Persistent negative margins limit internal funding capacity, make profitability dependent on substantial growth or cost reductions, and weaken the durability of the business model.

High Cash BurnThe company continues to consume substantial cash while funding its operations and development activities. High cash burn relative to revenue can require repeated external financing, potentially limiting strategic flexibility and increasing dependence on successful commercialization or additional capital.

Negative Equity And LeverageNegative equity is a material solvency warning and leaves little balance-sheet flexibility to absorb setbacks or fund growth. With debt still outstanding and total assets declining versus prior years, the company appears increasingly reliant on external funding to sustain its activities.

OncoZenge AB News

OncoZenge’s BupiZenge Heads Into Phase III: What This Pain Study Means for Investors

OncoZenge AB ($DE:8LY) announced an update on their ongoing clinical study. The phase III trial “A Randomized, Open-label,...

3M ago

8LY

8LY FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was €0.27 and its highest was €0.63 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is €7.08M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is Nov 11, 2026 which is in 41 days.

How were OncoZenge AB’s earnings last quarter?

OncoZenge AB released its earnings results on Aug 27, 2026. The company reported -€0.03 earnings per share for the quarter.

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 25,048,912 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

OncoZenge AB reported an EPS of -€0.03 in its last earnings report. Following the earnings report the stock price went up 5.288%.

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in DE:8LY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).